Zelluna Asa · OSL:ZLNA
Zelluna Asa — Ultimovacs — H1 2019 Earnings Presentation
14 slides from Zelluna Asa's earnings presentation, Aug 21, 2019
Slide 1: Activating the immune system to fight cancer
Activating the immune system to fight cancer First half 2019 presentation 21 August 2019 Øyvind Kongstun Arnesen, CEO Hans Vassgård Eid, CFO | Strictly private and confidential
Slide 2: Important notice and Disclaimer
Important notice and Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Ultimovacs’ business, financia
Slide 3: Ultimovacs – brief overview
Ultimovacs – brief overview Ultimovacs is a research based pharmaceutical company focused on developing universal cancer vaccines applicable at all stages of cancer, including possibly prevention of cancer Ultimovacs’ lead product, UV1, is a universal cancer vaccine developed to enable the immune sy
Slide 4: UV1 is a CD4 Activating, Universal Cancer Vaccine
UV1 is a CD4 Activating, Universal Cancer Vaccine UV1 is directed towards hTERT, which is expressed in 85-90% of all cancer indications UV1 can be used in the general population without pre-screening of HLA The UV1 vaccine consists of long peptides activating CD4 helper T lymphocytes UV1 is easily m
Slide 5: Ultimovacs – Development Plan
Ultimovacs – Development Plan 2018 2019 2020 2021 2022 2023 Metastatic malignant melanoma trial (Phase I, N=20 (TBC: up to 30), UV1/pembrolizumab) Ultimovacs sponsored UV1 Phase II proof of concept trial (first line metastatic malignant Preparations melanoma with triple combination ipilimumab/nivolu
Slide 6: Phase II trial in First Line Malignant Melanoma Patients
Phase II trial in First Line Malignant Melanoma Patients Indicated for Combination Treatment with Nivolumab/Ipilimumab Proof of concept trial to compare treatment with UV1/anti-PD1/anti-CTLA-4 versus anti-PD1/anti-CTLA-4 in patients that are indicated for anti-PD1/anti-CTLA-4 treatment Background an
Slide 7: Highlights – First half of 2019 (H1-2019)
Highlights – First half of 2019 (H1-2019) Clinical trial update Ongoing US based phase I trial study in malignant melanoma UV1 is given in combination with the PD-1 checkpoint inhibitor pembrolizumab. As per 30 June 2019, 15 out of the originally planned 20 patients have been included in this trial.
Slide 8: Highlights – First half of 2019 (H1-2019)
Highlights – First half of 2019 (H1-2019) Clinical trial update (cont.) Upcoming randomized phase II trial in malignant melanoma UV1 will be given in combination with the CTLA-4 checkpoint inhibitor ipilimumab and the PD-1 checkpoint inhibitor nivolumab Preparations are progressing according to plan
Slide 9: Highlights – First half of 2019 (H1-2019)
Highlights – First half of 2019 (H1-2019) European patent approval for UV1 In June 2019, the European Patent Office decided to grant Ultimovacs patent approval for UV1 This gives patent protection for UV1 in Europe until 2031 Patents for UV1 are now granted in Europe, the USA, Japan, Russia and Chin
Slide 10: Highlights – First half of 2019 (H1-2019)
Highlights – First half of 2019 (H1-2019) Successful completion of initial public offering First day of trading on the Oslo Stock Exchange was 3 June 2019 (ticker ‘ULTIMO’) MNOK 370 raised in the IPO (gross proceeds) The new shares issued represent 42.5% of total issued shares after the IPO The pric
Slide 11: Key financials
Key financials Key financials per H1-2019 - Ultimovacs Group Comments: NOK (000) H1-18 H2-18 H1-19 FY18 Total revenues 0 0 0 0 Payroll expenses Payroll and payroll related expenses 10 483 16 594 2 821 27 078 External R&D and IPR expenses 10 118 9 283 10 007 19 401 H2-18 includes an expense of MNOK O
Slide 12: Expected near-term milestones
Expected near-term milestones H2 2019 Regulatory response on a cohort with 10 additional patients in the ongoing US phase I trial Q4 2019/Q1 2020 Recruitment of patients completed in the ongoing US phase I trial H2 2019 5-years OS data from prostate cancer phase 1 Q1 2020 Initiation (first patient i
Slide 13: For questions
For questions Øyvind Kongstun Arnesen, CEO E-mail: oeyvind.arnesen@ultimovacs.com Phone: +47 469 33810 Hans Vassgård Eid, CFO E-mail: hans.eid@ultimovacs.com Phone: +47 469 19822 | 13 Strictly private and confidential
Slide 14: Q&A
Q&A | Strictly private and confidential